Table 3.
Summary of the quantitative tau burden analysis results.
| Antibody | DS-Cx | sAD-Cx | DS-WM | sAD-WM | p-Value (Cx/WM) * |
|---|---|---|---|---|---|
| Mean total deposition burden in all cases (range) [N = 10 and 9 cases, respectively] | |||||
| AT8 | 56.9 ± 19.1 (16.9–77.0) | 46.2 ± 13.9 (15.3–65.2) | 6.0 ± 2.8 (1.0–10.9) | 2.4 ± 1.2 (0.5–4.6) | 0.18/<0.01 |
| AT180 | 53.4 ± 18.9 (12.4–73.9) | 39.5 ± 13.0 (13.7–56.2) | 5.8 ± 2.6 (0.9–10.1) | 2.2 ± 1.1 (0.6–4.0) | 0.07/<0.01 |
| PHF13.6 | 21.7 ± 16.0 (0.9–45.6) | 18.9 ± 9.9 (0.2–38.7) | NA ** | NA ** | 0.60/NE |
| Alz50 | 5.7 ± 3.6 (1.3–12.6) | 3.9 ± 2.2 (1.0–7.3) | 1.2 ± 0.6 (0.3–2.6) | 0.6 ± 0.3 (0.1–1.2) | 0.40/0.02 |
| MC1 | 6.3 ± 8.6 (0.4–30.6) | 2.2 ± 1.9 (0.2–6.3) | 0.5 ± 0.4 (0.2–1.6) | 0.4 ± 0.2 (0.2–0.8) | 0.24/0.28 |
| GT38 | 3.1 ± 3.1 (0.0–8.6) | 0.9 ± 0.8 (0.0–2.4) | 0.2 ± 0.2 (0.0–0.9) | 0.2 ± 0.2 (0.0–0.7) | 0.32/0.97 |
| Mean total deposition burden in Braak NFT stage VI cases (range) [N = 8, 6 cases, respectively] | |||||
| AT8 | 64.2 ± 12.5 (44.0–77.0) | 50.9 ± 10.4 (32.7–65.2) | 6.8 ± 2.4 (3.6–10.9) | 2.8 ± 1.1 (1.0–4.6) | 0.11/<0.01 |
| AT180 | 61.1 ± 11.0 (38.3–73.9) | 43.5 ± 11.2 (22.7–56.2) | 6.6 ± 2.1 (4.1–10.1) | 2.6 ± 1.0 (0.9–4.0) | 0.01/<0.01 |
| PHF13.6 | 26.8 ± 13.6 (2.9–45.6) | 22.8 ± 7.9 (12.5–38.7) | NA ** | NA ** | 0.49/NE |
| Alz50 | 6.7 ± 3.4 (2.8–12.6) | 5.1 ± 1.5 (3.3–7.3) | 1.3 ± 0.6 (0.9–2.6) | 0.7 ± 0.3 (0.4–1.2) | 0.76/<0.01 |
| MC1 | 7.7 ± 9.0 (1.0–30.6) | 3.1 ± 1.7 (1.4–6.3) | 0.6 ± 0.4 (0.2–1.6) | 0.4 ± 0.2 (0.2–0.8) | 0.41/0.57 |
| GT38 | 3.9 ± 3.0 (0.1–8.6) | 1.1 ± 0.9 (0.1–2.4) | 0.1 ± 0.1 (0.0–0.3) | 0.2 ± 0.2 (0.0–0.7) | 0.18/1.00 |
Boldface signifies values that are significant at p < 0.05. Abbreviations: Cx, cortex; NA, not available; NFT, neurofibrillary tangle; WM, white matter. * Comparison between the DS and sAD groups using Mann–Whitney U test. ** Mean values could not be measured due to intense nonspecific background immunoreactivity.